Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 18/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | MTOR | P42345 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2858162 | 1.00 | TACR1 (0.55) | TACR1NPC1MTORRAB9A | |
| SCHEMBL2858767 | 1.00 | TACR1 (0.55) | TACR1NPC1MTORRAB9A | |
| SCHEMBL2785002 | 1.00 | TACR1 (0.55) | TACR1NPC1MTORRAB9A | |
| SCHEMBL8800656 | 1.00 | TACR1 (0.55) | TACR1NPC1MTORRAB9A | |
| SCHEMBL699568 | 0.87 | CHRNA7 (0.49) | TACR1NPC1MTORRAB9A | |
| SCHEMBL8800779 | 0.87 | TACR1 (0.51) | TACR1 | |
| SCHEMBL14364969 | 0.79 | TACR1 (0.55) | TACR1NPC1MTORRAB9A | |
| SCHEMBL14364850 | 0.79 | TACR1 (0.55) | TACR1 | |
| SCHEMBL9185372 | 0.79 | TACR1 (0.55) | TACR1NPC1MTORRAB9A | |
| SCHEMBL6135412 | 0.79 | TACR1 (0.55) | TACR1NPC1MTORRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7687630-B2 | Method for producing optically active quinuclidinols having one or more substituted groups at the 2-position | KANTO KAGAKU KABUSHIKI KAISHA (JP) | 2010-03-30 | — | — | US | disclosed |
| US-20080081911-A1 | Method for producing optically active quinuclidinols having one or more substituted groups at the 2-position | KANTO KAGAKU KABUSHIKI KAISHA (JP) | 2008-04-03 | — | — | US | disclosed |
| EP-0499313-B1 | Azabicyclic compounds, pharmaceutical compositions containing them and their use in therapy | MERCK SHARP & DOHME (GB) | 1997-06-11 | — | — | EP | disclosed |
| US-5242930-A | AZABICYCLIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE IN THERAPY | MERCK SHARP & DOHME LTD. | 1993-09-07 | — | — | US | disclosed |
| EP-0499313-A1 | Azabicyclic compounds, pharmaceutical compositions containing them and their use in therapy | MERCK SHARP & DOHME LTD. (GB) | 1992-08-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080081911-A1 | Method for producing optically active quinuclidinols having one or more substituted groups at the 2-position | NQO1, SQLE, NQO2 | TACR1 2370/4885NPC1 2003/4885MTOR 4412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.